Background and Study Aims: When stents are placed across the esophagogastric junction for palliative treatment of malignant strictures, they may lead to esophagogastric reflux. The aim of this study was to compare the effectiveness of a newly designed antireflux stent with that of a standard open stent and a current− ly available antireflux stent (Dostent) in preventing gastroesoph− ageal reflux symptoms in patients with inoperable cancer at the esophagogastric junction. Patients and Methods: Thirty−six consecutive patients with cancer at the esophagogastric junction were randomly assigned to undergo placement of a newly designed antireflux stent (n = 12), a Dostent (n = 12), or a standard open stent (n = 12). Technical and clinical success, dysphagia score, reflux symptoms, complications and ambulatory 24−h esophageal pH monitoring were assessed. Results: The technical success rates were 100 %. After 1 week, dysphagia had improved in all patient groups (P < 0.05), but the degree of improvement did not differ between the three groups. The DeMeester score was significantly lower in the group with the newly designed antireflux stent than in the other groups. The fraction of the total recording time during which esophageal pH was below 4 was 3.14 5.78 % using the newly designed anti− reflux stent, in comparison with 29.25 15.41 % in the Dostent group and 15.01 11.72 % in the standard open stent group (P < 0.001). Fewer reflux episodes occurred with the newly de− signed antireflux stent than with the Dostent or standard open stent. There were no complications with any of the three stents. Conclusions: The newly designed antireflux stent is effective in relieving dysphagia caused by malignant cancer at the esophago− gastric junction. The newly designed antireflux stent is signifi− cantly more effective in preventing gastroesophageal reflux than currently available antireflux stents. [5 ± 9] . However, few studies have investigated the efficacy of SEMS with an antireflux mechanism using objective methods such as ambulatory 24 h esophageal pH monitoring. The aim of the present study was to compare the effectiveness of a newly designed antireflux stent with that of a standard open stent and a currently available antireflux stent (Dostent) in patients with inoperable esophagogastric junction cancer, using ambulatory 24 h esophageal pH monitoring.
Patients and Methods

Patients
From July 2001 to March 2004, 36 consecutive patients with dys− phagia caused by inoperable carcinoma of the esophagogastric junction were randomly assigned to undergo insertion of either a newly designed antireflux stent, a Dostent, or a standard open stent. Patients with incurable malignant esophageal strictures involving the esophagogastric junction or within 2 cm of the esophagogastric junction were included. Patients with benign strictures, previous esophagogastric surgery, high portal blood pressure, coagulation disorders, pregnant or breastfeeding wom− en, and terminally ill patients with an estimated life expectancy of less than 6 weeks were excluded. There were 32 men and four women, aged 49 ± 83 years (mean 65.7 years). Twenty−eight pa− tients had squamous−cell carcinoma of the distal esophagus, sev− en patients had advanced gastric cancer with distal esophageal invasion, and one patient had gastric lymphoma. The diagnosis was established by means of endoscopic biopsy and computed tomography. In these 36 patients, 12 received standard open stents, 12 received Dostents, and 12 received the newly designed antireflux stent.
Stent Design
The standard open stent is a covered self−expandable metal stent (M.I. Tech. Co., Inc., Pyongtack, Korea). The stent is made from a strand of nitinol wire. The individual stent bodies have an inter− nal diameter of 18 mm and a length of 20 mm. Multiple stent bodies can be interconnected with a polyurethane membrane to produce stents of 4 ± 18 cm in length. The stent is flare−shaped, with flanges at the proximal and distal ends measuring 24 mm in diameter. The stent is completely covered with a polyurethane membrane. The Dostent (M.I. Tech. Co., Inc., Pyongtack, Korea) is an early−model antireflux stent dating from 1996 in which the valve was manufactured into the shape of a tricuspid valve. The stent has a disconnected body and the material used for both the valve and the covering is polyurethane. The valve is placed on the inner aspect of the stent's distal end. The leaflet contacting the three wings of the valve is 1 mm in length and 30 mm in diame− ter ( Figure 1 ). This product had problems in functioning properly when the reflux pressure was high, with the valve easily flipping over or small gaps occurring at the contact points of the tricuspid valve. A new model was therefore designed.
The modified antireflux stent (M.I. Tech. Co., Inc., Pyongtack, Korea) is an esophageal stent that is fully covered except for the proximal flange, to impede tumor ingrowth through the wire mesh, which has an S−type antireflux valve with a long leaflet in− side the stent body. The antireflux valve is attached to the stent wall in order to minimize acid reflux and prevent inversion of the valve ( Figure 2 ). The length of the valve's leaflet is 70 mm and its diameter at 18 mm is smaller than that of the earlier models be− cause of its position within the body of the stent. However, it has Figure 2 The newly designed antireflux stent (with an S−type valve and long leaf− lets). This modified antireflux stent is an esophageal stent that is fully covered, ex− cept for the proximal flange, to impede tu− mor ingrowth through the wire mesh, which has an S−type valve with long leaflets inside the stent's body. The antireflux valve is at− tached to the stent wall in order to mini− mize acid reflux and prevent inversion of the valve. Figure 1 The Dostent. The stent has a disconnected body, and the material used for both the valve and the covering is polyurethane. The valve is placed on the inner aspect of the stent's distal end and has the shape of a tricuspid valve. a As seen from the upper end of the stent. b As seen from the lower end.
a strong antireflux effect, as it uses an S−type valve with a long leaflet and the open inner diameter of the valve is small at 17.4 mm.
Stent Insertion Procedures
This prospective study was approved by the ethics committee of Soon Chun Hyang University. In all cases, informed consent was obtained from the patients before the procedure. All of the pa− tients had dysphagia at the initial evaluation. Dysphagia was graded on a scale of 0 to 4 (0, no dysphagia; 1, dysphagia to reg− ular solids; 2, dysphagia to soft solids; 3, dysphagia to solids and liquids; 4, complete dysphagia including saliva). A reflux symp− tom score was also evaluated using a questionnaire ( Table 1) . Each stenting procedure was carried out with the patient under intravenous conscious sedation using 2 ± 5 mg midazolam hy− drochloride and nalbuphine 10 mg for optimal effect. The phar− ynx was anesthetized with 2 % viscous lidocaine (Taejoon Phar− maceutical Co., Seoul, Korea). Oxygen was administered via a na− sal cannula, and the patient's vital signs were continuously mon− itored during the procedure. The procedures were all conducted with endoscopic and fluoroscopic visualization. In patients with tight strictures, preinsertion dilation was carried out using a Sa− vary±Gilliard bougie dilator under fluoroscopic guidance. To pre− vent stent migration, the stents were inserted in all cases using the technique described by Shim et al. [10] , in which the silk thread attached to the proximal flange of the stent is drawn out and attached to the patient's earlobe. After placement of a 0.038− inch stiff guide wire in the stomach, the stent introducer was ad− vanced over the guide wire into the esophagus under fluoro− scopic guidance, and the stent was deployed by pulling back the introducer sheath.
Follow−Up
Proton−pump inhibitors and other antacid medications were not prescribed. The patients ingested a liquid diet on the first day after the procedure, were restricted to a soft diet for 2 days, and then progressed to a soft diet. Clinical and radiographic check−up examinations were subsequently scheduled on days 1 and 7 and every 4 weeks thereafter. To evaluate the status of the valve and correct positioning of the stent, endoscopic examinations were carried out on the fifth to seventh days after insertion of the stent. After confirmation of complete fixation of the stent to the esophageal mucosa, the silk thread connected to the patient's earlobe was removed. Gastroesophageal reflux into the esopha− gus was assessed using ambulatory 24 h esophageal pH monitor− ing, with pH electrodes positioned just above the upper flange of the stent. This examination was carried out on the seventh day after stent placement. The dysphagia score and reflux symptom score were reevaluated on day 7. Endoscopic and radiographic examinations were repeated if there was recurrent dysphagia or reflux symptoms.
Statistical analysis. The data are presented as means plus or minus standard deviation (SD). All statistical analyses were car− ried out using the SPSS software package (SPSS Inc., Chicago, Illi− nois, USA). The statistical significance of differences for non−nor− mally distributed data was tested with the Mann±Whitney U test. The data were compared using the Kruskal±Wallis test for independent samples between groups. A P value of less than 0.05 was regarded as significant.
Results
The patients' demographic data are summarized in Table 2 . No statistical differences were observed with regard to age, sex, his− tology, or mean stricture length. Stent insertion was technically successful in all of the patients, and no procedure−related com− plications occurred in any of the three groups. The stent usually showed some waisting at the site of the stricture immediately after insertion, but expanded fully after a few days. All of the pa− tients had some dull chest pain following insertion for a few days. After stent placement, all of the patients had immediate improvement of their dysphagia (P < 0.05). The effectiveness of the palliative treatment for dysphagia was similar in all of the stent groups, with no statistically significant differences. In group A (standard open stent), the mean reflux symptom score increased from 4.42 3.40 to 6.25 2.70 (P = 0.049) after stent placement. Five patients in group A reported severe nocturnal re− flux symptoms. In group B (Dostent), the mean reflux symptom score increased from 5.58 3.40 to 5.75 6.15 (P = 0.798). Four patients in group B reported severe nocturnal reflux symptoms, and one patient developed aspiration pneumonia. By contrast, in group C (the newly designed antireflux stent), the mean reflux Original Article symptom score decreased from 5.42 3.40 to 2.50 1.78 (P = 0.005) after stent placement, and none of the patients re− ported nocturnal reflux symptoms or developed aspiration pneumonia ( Table 3) . The results of ambulatory 24 h esophageal pH monitoring are shown in Table 4 . The DeMeester score was significantly lower in group C than in the other groups (group A, 60.44 48.66; group B, 105.29 51.96; group C, 12.00 21.51; P < 0.001). The fraction of the total recording time during which esophageal pH was below 4 was only 3.14 5.78 % using the new− ly designed antireflux stent, compared with 15.01 11.72 % with the standard open stent and 29.2515.41 % with the Dostent (P < 0.001). Fewer reflux episodes occurred with the newly de− signed antireflux stent than with the Dostent and standard open stent (group A, 87.50 58.99; group B, 68.75 61.52; group C, 24.00 55.39; P = 0.002). No differences were detectable with re− gard to complications, need for repeat interventions, or survival periods. The 30−day mortality rate was 8 % in group A, 9 % in group B, and 12 % in group C; the median survival periods were 114 days, 107 days, and 109 days, respectively.
Discussion
With the rising incidence of carcinoma involving the distal esophagus and gastric cardia, self−expanding metal stents are in− creasingly being deployed across the esophagogastric junction. This can lead to significant gastroesophageal reflux and aspira− tion pneumonia, which can in turn adversely affect the patients' quality of life. With a stent deployed across the esophagogastric junction, the stomach and the esophagus in effect become a common cavity. In addition to reflux resulting from an increase in intra−abdominal pressure, patients with SEMS also may ex− perience "passive reflux" when gravity is eliminated [8] . To re− solve this problem, several attempts have been made in recent years to develop esophageal stents with an antireflux mecha− nism. Nunes et al. [6] and Valbuena [5] attached latex sleeves to rigid plastic esophageal stents. Mizumoto et al. [7] used a cylin− drical Gore−Tex modification to prevent reflux. Dua et al. [8] de− signed a modified self−expanding metal esophageal Z−stent to prevent reflux. The stent was modified by extending the polyu− rethane coating beyond the lower metal cage so as to form a "windsock" type of valve. The authors reported that this antire− flux stent was effective in preventing reflux without interfering with physiological flow.
Several trials have been conducted in Korea in the effort to devel− op an ideal antireflux stent. In 1993, a modified self−expanding metal esophageal stent was developed to prevent reflux. The morphology of this stent was similar to that of the stent designed by Dua et al. [8] , but it had certain limitations: insertion is more difficult with this type of stent than with conventional stents, and the antireflux valve can easily become inverted when high− pressure gradients occur ± e. g., during belching, vomiting, and coughing. Once it has become inverted, it is difficult to revert the valve by drinking water, and an endoscopic procedure is sometimes needed to revert the valve.
In 1996, another modified antireflux esophageal stent (Dostent, M.I. Tech. Co., Inc., Pyongtack, Korea) was produced. This is a fully covered esophageal stent that has an antireflux valve with a larger distal band in order to prevent reflux. The antireflux valve consists of three leaflets, like the tricuspid valve in the heart. The valves are made of polyurethane and attached to the inner por− tion of distal end of the stent. Most patients who received this stent experienced relief of reflux symptoms, but some were found to have acid reflux on 24 h pH monitoring, with endo− scopic examination showing that the valve had become reversed or distorted. A new model was therefore designed. This modified antireflux stent is a fully covered esophageal stent that has an S− type valve with long leaflets inside the body of the stent. The an− tireflux valve is attached to the stent wall in order to minimize acid reflux and prevent inversion of the valve.
Objective assessment of gastroesophageal reflux requires radio− graphic, scintigraphic, manometric, or pH monitoring tech− niques. Although barium and scintigraphic studies were not car− ried out in the present study, 24 h pH monitoring is the most re− liable method of diagnosing gastroesophageal reflux disease. In this study, the modified antireflux stent was compared with con− ventional self−expandable metal stents and Dostents with regard to reflux symptoms, dysphagia score, and the ambulatory 24 h pH monitoring results. The dysphagia score improved signifi− cantly with all of the stents. Of the three stents, the newly de− signed S−type antireflux valve was found to the best for prevent− ing acid reflux on ambulatory 24 h pH monitoring. The modifica− tion does not appear to interfere with the primary function of the stent−relieving dysphagia. On the basis of this experience with the new antireflux valve stent, we believe that the S−type valve Original Article with long leaflets is more effective than conventional stents and the previous Dostent in preventing acid reflux and valve inver− sion.
